Despite having appreciated 20% in a year, Celgene Corporation (NASDAQ:CELG) shares are still a reasonable buy for growth.
What does Celgene do?
Celgene is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs. The company operates in more than 60 countries and sells its products in more than 70.
In 2016, Celgene generated sales of $11.2 billion. Its expertise lies in hematology, oncology, and immunology. Here’s an overview of Celgene’s key products:
|Product||2016 Sales (million)||% of 2015 Sales||% of 2016 Sales||YOY growth|
Revlimid remains as Celgene’s core drug from 2015 and its market in the multiple myeloma space is still growing.